- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT03734029
Trastuzumab Deruxtecan (DS-8201a) versus volba výzkumníka pro karcinom prsu s nízkou HER2, který se rozšířil nebo jej nelze chirurgicky odstranit [DESTINY-Breast04]
Fáze 3, multicentrická, randomizovaná, otevřená, aktivně kontrolovaná studie DS-8201a, konjugátu léku proti HER2 (ADC), versus léčba podle volby lékaře u pacientů s nízkým HER2, neresekovatelným a/nebo metastatickým karcinomem prsu
This study will compare DS-8201a to physician choice standard treatment.
Participants must have HER2-low breast cancer that has been treated before.
Participants' cancer:
- Cannot be removed by an operation
- Has spread to other parts of the body
Přehled studie
Postavení
Podmínky
Detailní popis
This is a randomized, 2-arm, Phase 3, open-label, multicenter study to compare the safety and efficacy of trastuzumab deruxtecan versus the physician's choice (2:1) in HER2-low, unresectable and/or metastatic breast cancer participants.
The Sponsor proposes to define a new HER2-low population in this trial including tumors with IHC 1+ and IHC 2+/ISH- HER2 expression.
Typ studie
Zápis (Aktuální)
Fáze
- Fáze 3
Kontakty a umístění
Studijní místa
-
-
-
Brussels, Belgie, 1000
- Institut Jules Bordet
-
Brussels, Belgie, 1090
- Universitair Ziekenhuis Brussel
-
Brussels, Belgie, 1200
- Cliniques Universitaires Saint-Luc
-
Leuven, Belgie, 3000
- UZ Leuven
-
Loverval, Belgie, 6280
- Grand Hôpital de Charleroi
-
Namur, Belgie, 5000
- CHU UCL Namur
-
Tournai, Belgie, 7500
- Centre Hospitalier Wallonie picarde - Site IMC
-
-
-
-
-
Paris, Francie, 75020
- Hopital Tenon
-
Paris, Francie, 75005
- Institut Curie - site de Paris
-
-
Bouches-du-Rhône
-
Marseille, Bouches-du-Rhône, Francie, 13009
- Institut Paoli Calmettes
-
-
Calvados
-
Caen, Calvados, Francie, 14076
- Centre François Baclesse
-
-
Cotes d'Armor
-
Plérin, Cotes d'Armor, Francie, 22190
- CARIO - Centre Armoricain de Radiothérapie, Imagerie médicale et Oncologie
-
-
Finistere
-
Brest, Finistere, Francie, 29609
- CHU Brest - Hôpital Morvan
-
-
Gironde
-
Bordeaux, Gironde, Francie, 33076
- Institut Bergonié
-
-
Herault
-
Montpellier, Herault, Francie, 34070
- Clinique Clementville
-
Montpellier, Herault, Francie, 34298
- Institut Régional du Cancer de Montpellier
-
-
Ille Et Vilaine
-
Rennes, Ille Et Vilaine, Francie, 35042
- CRLCC Eugene Marquis
-
-
Loire Atlantique
-
Saint-Herblain, Loire Atlantique, Francie, 44805
- ICO - Site René Gauducheau
-
-
Loiret
-
Le Puy-en-Velay, Loiret, Francie, 43012
- Centre Hospitalier Emile Roux
-
-
Maine Et Loire
-
Angers, Maine Et Loire, Francie, 49055
- ICO - Site Paul Papin
-
-
Nord
-
Valenciennes, Nord, Francie, 59322
- Centre Hospitalier Valenciennes
-
-
Paris
-
Paris, Paris, Francie, 75475
- Hôpital Saint-Louis - Paris
-
-
Sarthe
-
Le Mans, Sarthe, Francie, 72015
- Clinique Victor Hugo - Centre Jean Bernard
-
-
Vaculuse
-
Avignon, Vaculuse, Francie, 84918
- Institut Sainte Catherine
-
-
Val De Marne
-
Saint-Mandé, Val De Marne, Francie, 94160
- Hôpital d'Instruction des Armees Begin*
-
Villejuif, Val De Marne, Francie, 94805
- Institut Gustave Roussy
-
-
-
-
-
Bologna, Itálie, 40138
- Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi
-
Brescia, Itálie, 25100
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (Presidio Spedali Civili)
-
Catania, Itálie, 95125
- Azienda Ospedaliera Univ. Policlinico Gaspare Rodolico
-
Catanzaro, Itálie, 88100
- Azienda Ospedaliero Universitaria Mater Domini-Campus Universitario
-
Milan, Itálie, 20141
- IEO Istituto Europeo di Oncologia
-
Naples, Itálie, 80131
- Istituto Nazionale Tumori Fondazione G. Pascale
-
Rimini, Itálie, 47923
- Ospedale degli Infermi
-
Roma, Itálie, 00168
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
-
Roma, Itálie, 00133
- Azienda Ospedaliera Universitaria Policlinico Tor Vergata
-
-
Lecce
-
Tricase, Lecce, Itálie, 73039
- Azienda Ospedaliera Card. G. Panico
-
-
Milano
-
Monza, Milano, Itálie, 20900
- Azienda Socio Sanitaria Territoriale di Monza (Presidio San Gerardo)
-
Rozzano, Milano, Itálie, 20089
- Istituto Clinico Humanitas
-
-
Verona
-
Negrar, Verona, Itálie, 37024
- Ospedale Sacro Cuore Don Calabria
-
-
-
-
-
Haifa, Izrael, 3109601
- Rambam Health Care Center
-
Jerusalem, Izrael, 9103102
- Shaare Zedek Medical Center
-
Jerusalem, Izrael, 9112001
- Hadassah University Hospital - Ein Kerem
-
Petah Tikva, Izrael, 49100
- Rabin Medical Center-Beilinson Campus
-
Ramat Gan, Izrael, 52363
- Chaim Sheba Medical Center
-
Rehovot, Izrael, 7610001
- Kaplan Medical Center
-
Safed, Izrael, 13100
- Ziv Medical Center
-
Tel Aviv, Izrael, 6423906
- Tel Aviv Sourasky Medical Center
-
-
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japonsko, 464-8681
- Aichi Cancer Center Hospital
-
-
Chiba
-
Kashiwa-shi, Chiba, Japonsko, 277-8577
- National Cancer Center Hospital East
-
-
Ehime
-
Matsuyama, Ehime, Japonsko, 791-0280
- NHO Shikoku Cancer Center
-
-
Fukuoka
-
Fukuoka, Fukuoka, Japonsko, 811-1395
- NHO Kyushu Cancer Center
-
-
Fukushima
-
Fukushima, Fukushima, Japonsko, 960-1295
- Fukushima Medical University Hospital
-
-
Hiroshima
-
Hiroshima, Hiroshima, Japonsko, 730-8518
- Hiroshima City Hiroshima Citizens Hospital
-
-
Hokkaido
-
Sapporo, Hokkaido, Japonsko, 003-0804
- NHO Hokkaido Cancer Center
-
-
Hyōgo
-
Nishinomiya-shi, Hyōgo, Japonsko, 663-8501
- Hyogo College of Medicine Hospital
-
-
Kagoshima-ken
-
Kagoshima, Kagoshima-ken, Japonsko, 892-0833
- Hakuaikai Sagara Hospital
-
-
Kanagawa
-
Isehara, Kanagawa, Japonsko, 259-1193
- Tokai University Hospital
-
Yokohama, Kanagawa, Japonsko, 241-8515
- Kanagawa Cancer Center
-
-
Osaka
-
Osaka, Osaka, Japonsko, 540-0006
- NHO Osaka National Hospital
-
-
Osakasayama-shi
-
Onohigashi, Osakasayama-shi, Japonsko, 589-8511
- Kindai University Hospital
-
-
Saitama
-
Kitaadachi-gun, Saitama, Japonsko, 362-0806
- Saitama Cancer Center
-
-
Shizuoka
-
Sunto-gun, Shizuoka, Japonsko, 411-8777
- Shizuoka Cancer Center
-
-
Tokyo-To
-
Kōtoku, Tokyo-To, Japonsko, 135-8550
- Cancer Institute Hospital of JFCR
-
Minatoku, Tokyo-To, Japonsko, 105-8470
- Toranomon Hospital
-
Shinagawa-Ku, Tokyo-To, Japonsko, 142-8666
- Showa University Hospital
-
-
-
-
-
Daegu, Jižní Korea, 41404
- Kyungpook National University Chilgok Hospital
-
Seoul, Jižní Korea, 03080
- Seoul National University Hospital
-
Seoul, Jižní Korea, 05505
- Asan Medical Center
-
Seoul, Jižní Korea, 06351
- Samsung Medical Center
-
Seoul, Jižní Korea, 06591
- The Catholic University of Korea, Seoul St. Mary's Hospital
-
Seoul, Jižní Korea, 120-752
- Severance Hospital, Yonsei University Health System
-
-
Gyeonggi-do
-
Goyang-si, Gyeonggi-do, Jižní Korea, 10408
- National Cancer Center
-
Incheon, Gyeonggi-do, Jižní Korea, 22332
- Inha University Hospital
-
Seongnam-si, Gyeonggi-do, Jižní Korea, 13620
- Seoul National University Bundang Hospital
-
Suwon, Gyeonggi-do, Jižní Korea, 16499
- Ajou University Hospital
-
-
North Chungcheong
-
Cheongju-si, North Chungcheong, Jižní Korea, 361-711
- Chungbuk National University Hospital
-
-
-
-
Alberta
-
Calgary, Alberta, Kanada, T2N4N2
- Tom Baker Cancer Center
-
-
Ontario
-
Toronto, Ontario, Kanada, M4N 3M5
- Toronto Sunnybrook Hospital
-
-
Quebec
-
Montreal, Quebec, Kanada, H2W 1S6
- McGill University - Dept. Oncology Clinical Research Program
-
-
-
-
-
Budapest, Maďarsko, 1097
- Del-pesti Centrumkorhaz - Orszagos Hematologiai es Infektologiai Intezet
-
Budapest, Maďarsko, 1122
- Orszagos Onkologiai Intezet
-
Debrecen, Maďarsko, 4032
- Debreceni Egyetem
-
Gyula, Maďarsko, 5700
- Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaza
-
Nyíregyháza, Maďarsko, 4400
- SzSzB Megyei Korhazak es Egyetemi Oktatokorhaz
-
Szolnok, Maďarsko, 5004
- Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet
-
-
-
-
Baden-Wurttemberg
-
Heidelberg, Baden-Wurttemberg, Německo, 69120
- Universitaetsklinikum Heidelberg
-
-
Bavaria
-
Munich, Bavaria, Německo, 81377
- Klinikum der Universitaet Muenchen - Campus Grosshardern
-
-
-
-
-
Braga, Portugalsko, 4710-243
- Hospital de Braga
-
Guimarães, Portugalsko, 4835-044
- Centro Hospitalar do Alto do Ave, EPE
-
Lisbon, Portugalsko, 1649-035
- Centro Hospitalar de Lisboa Norte, E.P.E. - Hospital de Santa Maria
-
Lisbon, Portugalsko, 1400-038
- Fundação Champalimaud
-
Matosinhos Municipality, Portugalsko, 4464-509
- Unidade Local de Saúde de Matosinhos, EPE (Hospital Pedro Hispano)
-
Porto, Portugalsko, 4200-072
- Instituto Português de Oncologia do Porto Francisco Gentil, EPE
-
Porto, Portugalsko, 4099-001
- Centro Hospitalar do Porto, E.P.E. - Hospital de Santo António
-
Santa Maria da Feira, Portugalsko, 4520-211
- Centro Hospitalar de Entre o Douro e Vouga, E.P.E - Hospital de São Sebastião
-
Vila Nova de Gaia, Portugalsko, 4434-502
- Centro Hospitalar Vila Nova de Gaia/Espinho, E.P.E
-
Vila Real, Portugalsko, 5000-508
- Centro Hospitalar de Trás-os-Montes e Alto Douro, EPE
-
-
-
-
-
Innsbruck, Rakousko, 6020
- Medizinische Universität Innsbruck
-
Linz, Rakousko, 4020
- Kepler Universitätsklinikum
-
Salzburg, Rakousko, 5020
- LKH - Universitätsklinikum der PMU Salzburg
-
Vienna, Rakousko, 1090
- AKH - Medizinische Universität Wien (4305)
-
Wels, Rakousko, 4600
- Klinikum Wels-Grieskirchen GmbH
-
-
-
-
-
Moscow, Rusko, 115478
- FSBSI "Russian Oncological Scientific Center n.a. N.N. Blokhin"
-
Moscow, Rusko, 143423
- SBIH of Moscow City "Moscow City Oncology Hospital №62" of Moscow Healthcare Departement
-
Yaroslavl, Rusko, 150054
- SBIH of Yaroslavl Region "Regional Clinical Oncological Hospital"
-
-
-
-
Cornwall
-
Truro, Cornwall, Spojené království, TR1 3LJ
- Royal Cornwall Hospital
-
-
Greater London
-
London, Greater London, Spojené království, NW3 2QG
- Royal Free Hospital
-
London, Greater London, Spojené království, EC1M 6BQ
- Queen Mary University of London
-
London, Greater London, Spojené království, NW1 2PG
- University College London Hospitals
-
-
Lothian Region
-
Edinburgh, Lothian Region, Spojené království, EH4 2XU
- Western General Hospital
-
-
Nottinghamshire
-
Nottingham, Nottinghamshire, Spojené království, NG5 1PB
- Nottingham University Hospitals City Campus
-
-
Surrey
-
Guildford, Surrey, Spojené království, GU2 7XX
- Royal Surrey County Hospital
-
-
-
-
Arizona
-
Chandler, Arizona, Spojené státy, 85224
- Ironwood Cancer & Research Centers - Chandler II
-
Gilbert, Arizona, Spojené státy, 85234
- Banner MD Anderson Cancer Center
-
Goodyear, Arizona, Spojené státy, 85338
- Cancer Treatment Centers of America at Western Regional Medical Center
-
-
California
-
Los Angeles, California, Spojené státy, 90095
- UCLA School of Medicine
-
Palo Alto, California, Spojené státy, 94305
- Stanford Cancer Institute
-
Redondo Beach, California, Spojené státy, 90277
- Cancer Care Associates Medical Group, Inc. TORI
-
San Francisco, California, Spojené státy, 94158
- University of California at San Francisco (PARENT)
-
-
Connecticut
-
Norwich, Connecticut, Spojené státy, 06360
- Eastern Connecticut Hematology/Oncology Assoc.
-
-
Delaware
-
Newark, Delaware, Spojené státy, 19713
- Christiana Care Health Services, Inc.
-
-
Florida
-
Boca Raton, Florida, Spojené státy, 33426
- Sylvester Comprehensive Cancer Center - Deerfield Beach
-
Fort Myers, Florida, Spojené státy, 33916
- Florida Cancer Specialists (South Region)
-
Hollywood, Florida, Spojené státy, 33021
- Memorial Healthcare System MRH Cancer Center
-
Orlando, Florida, Spojené státy, 32806
- Orlando Health, Inc.
-
Tampa, Florida, Spojené státy, 33139
- Moffitt Cancer Center -Tampa
-
-
Georgia
-
Newnan, Georgia, Spojené státy, 30263
- Cancer Treatment Centers of America-Georgia
-
-
Illinois
-
Chicago, Illinois, Spojené státy, 60637
- University of Chicago Medical Center
-
Zion, Illinois, Spojené státy, 60099
- Cancer Treatment Centers of America
-
-
Kansas
-
Wichita, Kansas, Spojené státy, 67214
- Cancer Center of Kansas
-
-
Louisiana
-
New Orleans, Louisiana, Spojené státy, 70115
- Touro Infirmary
-
-
Massachusetts
-
Boston, Massachusetts, Spojené státy, 02215
- Dana-Farber Cancer Institute
-
-
Michigan
-
Detroit, Michigan, Spojené státy, 48202
- Henry Ford Hospital
-
-
Missouri
-
Kansas City, Missouri, Spojené státy, 64111
- Saint Luke's Hospital of Kansas City
-
-
New Jersey
-
Livingston, New Jersey, Spojené státy, 07039
- Saint Barnabas Medical Center
-
-
New York
-
New York, New York, Spojené státy, 10016
- New York University Medical Center
-
New York, New York, Spojené státy, 10065
- Memorial Sloan Kettering Hospital
-
New York, New York, Spojené státy, 10065
- Weill Cornell Medicine Breast Center
-
-
Ohio
-
Cleveland, Ohio, Spojené státy, 44195
- The Cleveland Clinic Foundation
-
-
Oregon
-
Portland, Oregon, Spojené státy, 97239
- Oregon Health & Science University
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Spojené státy, 15212
- Allegheny General Hospital
-
Pittsburgh, Pennsylvania, Spojené státy, 15219
- University of Pittsburgh Medical Center Health System
-
-
South Carolina
-
Greenville, South Carolina, Spojené státy, 29601
- St Francis Hospital
-
-
Tennessee
-
Knoxville, Tennessee, Spojené státy, 37909
- Brig Center for Cancer Care and Survivorship
-
Memphis, Tennessee, Spojené státy, 38120
- Baptist Cancer Center
-
Nashville, Tennessee, Spojené státy, 37201
- Tennessee Oncology - Skyline Satellite
-
-
Texas
-
Dallas, Texas, Spojené státy, 75234
- BloomTrials Clinical Research, LLC
-
Houston, Texas, Spojené státy, 77030
- The Methodist Hospital Research Institute
-
Houston, Texas, Spojené státy, 77030
- University of Texas M. D. Anderson Cancer Center - Investigational Cancer Therapeutics
-
-
Virginia
-
Fairfax, Virginia, Spojené státy, 22031
- Virginia Cancer Specialists
-
-
-
-
-
Kaohsiung City, Tchaj-wan, 807
- Kaohsiung Medical University Chung-Ho Memorial Hospital
-
Tainan, Tchaj-wan, 704
- National Cheng Kung University Hospital
-
Taipei, Tchaj-wan, 100
- National Taiwan University Hospital
-
-
-
-
Anhui
-
Hefei, Anhui, Čína, 230001
- Anhui Provincial Hospital
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Čína, 100853
- Chinese PLA General Hospital
-
Beijing, Beijing Municipality, Čína, 100021
- Cancer Hospital Chinese Academy of Medical Sciences
-
-
Fujian
-
Fuzhou, Fujian, Čína, 350025
- Fuzhou General Hospital of Nanjing Military Area Command of Chinese PLA
-
-
Guangdong
-
Guangzhou, Guangdong, Čína, 510120
- Sun Yat-sen Memorial hospital, Sun Yat-sen University
-
-
Heilongjiang
-
Harbin, Heilongjiang, Čína, 150081
- Harbin Medical University Cancer Hospital
-
-
Hubei
-
Wuhan, Hubei, Čína, 430079
- Hubei Cancer Hospital
-
-
Jiangsu
-
Nanjing, Jiangsu, Čína, 210008
- The Affiliated Drum Tower Hospital of Nanjing University
-
-
Jilin
-
Changchun, Jilin, Čína, 130000
- The First Hospital of Jilin University
-
Changchun, Jilin, Čína, 130012
- Jilin Cancer Hospital
-
-
Liaoning
-
Shenyang, Liaoning, Čína, 110042
- Liaoning Cancer Hospital & Institute
-
-
Ningxia Hui
-
Yinchuan, Ningxia Hui, Čína, 750004
- General Hospital of Ningxia Medical University
-
-
Shandong
-
Linyi, Shandong, Čína, 276001
- Linyi Cancer Hospital
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Čína, 200080
- Shanghai General Hospital
-
Shanghai, Shanghai Municipality, Čína, 20032
- Fudan University Shanghai Cancer Center
-
-
Sichuan
-
Chengdu, Sichuan, Čína, 610041
- West China Hospital, Sichuan University
-
-
Zhejiang
-
Hangzhou, Zhejiang, Čína, 310022
- Zhejiang Cancer Hospital
-
Hangzhou, Zhejiang, Čína, 310016
- Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine
-
-
-
-
-
Athens, Řecko, 15125
- Athens Medical Center
-
Athens, Řecko, 11528
- General Hospital of Athens "Alexandra"
-
Athens, Řecko, 14564
- General Oncology Hospital of Kifissia " Agioi Anargyroi"
-
Heraklion, Řecko, 71110
- University General Hospital of Heraklion
-
Larissa, Řecko, 41110
- University General Hospital of Larissa
-
Thessaloniki, Řecko, 54622
- Bioclinic Thessaloniki
-
Thessaloniki, Řecko, 54645
- Euromedica General Clinic Thessaloniki
-
Thessaloniki, Řecko, 56429
- General Hospital Papageorgiou
-
Thessaloniki, Řecko, 57001
- Interbalkan Hospital of Thessaloniki
-
-
-
-
-
Barcelona, Španělsko, 08036
- Hospital Clinic de Barcelona
-
Barcelona, Španělsko, 08035
- Hospital Universitari Vall d'Hebron
-
Barcelona, Španělsko, 08023
- Hospital Quironsalud Barcelona
-
Barcelona, Španělsko, 08003
- Hospital del Mar
-
Madrid, Španělsko, 28034
- Hospital Universitario Ramon y Cajal
-
Madrid, Španělsko, 28040
- Hospital Universitario Clinico San Carlos
-
Madrid, Španělsko, 28034
- Hospital Ruber Internacional
-
Madrid, Španělsko, 28033
- MD Anderson Cancer Centre
-
Málaga, Španělsko, 29010
- Hospital Clinico Universitario Virgen de la Victoria
-
Seville, Španělsko, 41009
- Hospital Universitario Virgen Macarena
-
Seville, Španělsko, 41013
- Hospital Universitario Virgen del Rocio
-
Valencia, Španělsko, 46014
- Hospital General Universitario de Valencia
-
Valencia, Španělsko, 46009
- Instituto Valenciano de Oncologia IVO
-
-
Barcelona
-
L'Hospitalet de Llobregat, Barcelona, Španělsko, 08908
- ICO l'Hospitalet - Hospital Duran i Reynals
-
-
Guipuzcoa
-
San Sebastián, Guipuzcoa, Španělsko, 20014
- Hospital Universitario Donostia
-
-
La Coruña
-
A Coruña, La Coruña, Španělsko, 15006
- Complejo Hospitalario Universitario A Coruña
-
-
Tenerife
-
San Cristóbal de La Laguna, Tenerife, Španělsko, 38320
- Hospital Universitario de Canarias
-
-
Vizcaya
-
Bilbao, Vizcaya, Španělsko, 48013
- Hospital de Basurto
-
-
-
-
-
Solna, Švédsko, 17176
- Karolinska universitetssjukhuset - Solna
-
Sundsvall, Švédsko, 85186
- Länssjukhuset Sundsvall-Härnösand
-
Uppsala, Švédsko, 75185
- Akademiska Sjukhuset
-
-
-
-
-
Aarau, Švýcarsko, 5000
- Hirslanden Medical Center
-
Basel, Švýcarsko, 4031
- Universitaetsspital Basel
-
Chur, Švýcarsko, 7000
- Kantonsspital Graubuenden
-
Lausanne, Švýcarsko, 1011
- Centre Hospitalier Universitaire Vaudois
-
Sankt Gallen, Švýcarsko, 9007
- Kantonsspital St. Gallen
-
Winterthur, Švýcarsko, 8401
- Kantonsspital Winterthur
-
Zurich, Švýcarsko, 8091
- Universitaetsspital Zuerich
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
-
Is the age of majority in their country
-
Has pathologically documented breast cancer that:
- Is unresectable or metastatic
- Has low-HER2 expression defined as IHC 2+/ISH- or IHC 1+ (ISH- or untested)
- Is HR-positive or HR-negative
- Has progressed on, and would no longer benefit from, endocrine therapy
- Has been treated with 1 to 2 prior lines of chemotherapy/adjuvant in the recurrent or metastatic setting
- Was never previously HER2-positive (ICH 3+ or ISH+) on prior pathology testing (per American Society of Clinical Oncology-College of American Pathologists [ASCO-CAP] guidelines)
-
Has documented radiologic progression (during or after most recent treatment)
-
Has adequate archival tumor samples available or is wiling to provide fresh biopsies prior to randomization for:
- assessment of HER2 status
- assessment of post-treatment status
-
Has at least 1 measurable lesion per Response Evaluation Criteria In Solid Tumors 1.1
-
Has protocol-defined adequate cardiac, bone marrow, renal, hepatic and blood clotting functions
-
Male and female participants of reproductive/childbearing potential, agrees to follow instructions for method(s) of contraception and agrees to avoid preserving ova or sperm for at least 4.5 months after treatment (or longer, per locally approved labels)
Exclusion Criteria:
- Is ineligible for all options in the physician's choice arm
- Has breast cancer ever assessed with high-HER2 expression
- Has previously been treated with any anti-HER2 therapy, including an antibody drug conjugate
- Has uncontrolled or significant cardiovascular disease
- Has spinal cord compression or clinically active central nervous system metastases
- Has history of (noninfectious) interstitial lung disease (ILD)/pneumonitis that required steroids, has current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening
- Has any medical history or condition that per protocol or in the opinion of the investigator is inappropriate for the study
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Trastuzumab deruxtecan
HER2-low, unresectable, and/or metastatic breast cancer participants previously treated with chemotherapy randomized to DS8201a |
DS-8201a is a lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered intravenously
Ostatní jména:
|
|
Aktivní komparátor: Physician's Choice
HER2-low, unresectable, and/or metastatic breast cancer participants previously treated with chemotherapy randomized to Physician's choice from the following options:
|
Administered according to label, as one option for Physician's Choice (determined before randomization) Administered according to label, as one option for Physician's Choice (determined before randomization) Administered according to label, as one option for Physician's Choice (determined before randomization) Administered according to label, as one option for Physician's Choice (determined before randomization) Administered according to label, as one option for Physician's Choice (determined before randomization) |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer
Časové okno: From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years
|
Progression-free survival (PFS), defined as at least a 20% increase in the sum of diameters of target lesions, was assessed from the date of randomization to the date of the first radiographic disease progression or death due to any cause, whichever came first. PFS was based on blinded independent central review (BICR) in the hormone receptor-positive cohort according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1. Median PFS was from Kaplan-Meier analysis. Confidence interval for median was computed using the Brookmeyer-Crowley method. |
From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Počet celkových událostí přežití (úmrtí)
Časové okno: Od data randomizace do data úmrtí z jakékoli příčiny, přibližně do 3 let
|
Od data randomizace do data úmrtí z jakékoli příčiny, přibližně do 3 let
|
|
|
Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-low Breast Cancer (All Patients) Regardless of Hormone Receptor Status
Časové okno: From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years
|
Progression-free survival (PFS), defined as at least a 20% increase in the sum of diameters of target lesions, was assessed from the date of randomization to the date of the first radiographic disease progression or death due to any cause, whichever came first. PFS was based on blinded independent central review (BICR) according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1. Median PFS was from Kaplan-Meier analysis. Confidence interval for median was computed using the Brookmeyer-Crowley method. |
From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years
|
|
Progression-free Survival Based on Investigator Assessment in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer
Časové okno: From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years
|
Progression-free survival (PFS), defined as at least a 20% increase in the sum of diameters of target lesions, was assessed from the date of randomization to the date of the first radiographic disease progression or death due to any cause, whichever came first. PFS was based on investigator assessment in the hormone receptor-positive cohort according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1. Median PFS was from Kaplan-Meier analysis. Confidence interval for median was computed using the Brookmeyer-Crowley method. |
From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years
|
|
Progression-free Survival Based on Investigator Assessment in Participants With HER2-low Breast Cancer (All Patients)
Časové okno: From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years
|
Progression-free survival (PFS), defined as at least a 20% increase in the sum of diameters of target lesions, was assessed from the date of randomization to the date of the first radiographic disease progression or death due to any cause, whichever came first. PFS was based on investigator assessment according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1. Median PFS was from Kaplan-Meier analysis. Confidence interval for median was computed using the Brookmeyer-Crowley method. |
From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years
|
|
Overall Survival (OS) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer
Časové okno: From the date of randomization up to the date of death due to any cause, up to approximately 3 years
|
Overall survival (OS) was defined as the time from the date of randomization to the date of death due to any cause. If there was no death reported for a participant before the data cutoff for OS analysis, OS was censored at the last contact date at which the participant was known to be alive. |
From the date of randomization up to the date of death due to any cause, up to approximately 3 years
|
|
Overall Survival (OS) in All Patients
Časové okno: From the date of randomization up to the date of death due to any cause, up to approximately 3 years
|
Overall survival (OS) was defined as the time from the date of randomization to the date of death due to any cause. If there was no death reported for a participant before the data cutoff for OS analysis, OS was censored at the last contact date at which the participant was known to be alive. |
From the date of randomization up to the date of death due to any cause, up to approximately 3 years
|
|
Best Overall Response and Confirmed Objective Response Rate (ORR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer
Časové okno: From screening and every 6 weeks up to withdrawal of subject consent, progressive disease (PD), or unacceptable toxicity, up to approximately 3 years
|
Best overall response rate and confirmed objective response rate (ORR) were assessed by blinded independent central review (BICR) and investigator assessment. Complete response (CR) was defined as a disappearance of all target lesions, partial response (PR) was defined as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions. Confirmed ORR was defined as the number of participants with complete and partial responses and confirmed by a second assessment. |
From screening and every 6 weeks up to withdrawal of subject consent, progressive disease (PD), or unacceptable toxicity, up to approximately 3 years
|
|
Best Overall Response and Confirmed Objective Response Rate (ORR) in Participants With HER2-low Breast Cancer (All Patients)
Časové okno: From screening and every 6 weeks up to withdrawal of subject consent, progressive disease (PD), or unacceptable toxicity, up to approximately 3 years
|
Best overall response rate and confirmed objective response rate (ORR) were assessed by blinded independent central review (BICR) and investigator assessment. Complete response (CR) was defined as a disappearance of all target lesions, partial response (PR) was defined as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions. Confirmed ORR was defined as the number of participants with complete and partial responses and confirmed by a second assessment. |
From screening and every 6 weeks up to withdrawal of subject consent, progressive disease (PD), or unacceptable toxicity, up to approximately 3 years
|
|
Duration of Response in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer
Časové okno: From the date of the first documented objective response (CR or PR) to the first documented disease progression or death, whichever occurs first, up to approximately 3 years
|
Duration of Response (DoR) is defined as the date of the first documented objective response (complete response [CR] or partial response [PR]) to the first documented disease progression or death, whichever occurs first. DoR was based on blinded independent central review (BICR) and investigator assessment. Median was from Kaplan-Meier estimate. Confidence interval for median was computed using the Brookmeyer-Crowley method. |
From the date of the first documented objective response (CR or PR) to the first documented disease progression or death, whichever occurs first, up to approximately 3 years
|
|
Duration of Response in Participants With HER2-low Breast Cancer (All Patients)
Časové okno: From the date of the first documented objective response (CR or PR) to the first documented disease progression or death, whichever occurs first, up to approximately 3 years
|
Duration of Response (DoR) is defined as the date of the first documented objective response (complete response [CR] or partial response [PR]) to the first documented disease progression or death, whichever occurs first. DoR was based on blinded independent central review (BICR) and investigator assessment. Median was from Kaplan-Meier estimate. Confidence interval for median was computed using the Brookmeyer-Crowley method. |
From the date of the first documented objective response (CR or PR) to the first documented disease progression or death, whichever occurs first, up to approximately 3 years
|
Další výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
All-Cause Mortality
Časové okno: From the date of randomization up to the date of death due to any cause, up to approximately 3 years
|
All-cause mortality is defined as all anticipated and unanticipated deaths due to any cause, with the number and frequency of such events by arm or comparison group of the clinical study. |
From the date of randomization up to the date of death due to any cause, up to approximately 3 years
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Ředitel studie: Global Clinical Leader, Daiichi Sankyo
Publikace a užitečné odkazy
Obecné publikace
- Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga JY, Im SA, Moore HCF, Rugo HS, Yerushalmi R, Zagouri F, Gombos A, Kim SB, Liu Q, Luo T, Saura C, Schmid P, Sun T, Gambhire D, Yung L, Wang Y, Singh J, Vitazka P, Meinhardt G, Harbeck N, Cameron DA; DESTINY-Breast04 Trial Investigators. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022 Jul 7;387(1):9-20. doi: 10.1056/NEJMoa2203690. Epub 2022 Jun 5.
- Jhaveri K, Eli LD, Wildiers H, Hurvitz SA, Guerrero-Zotano A, Unni N, Brufsky A, Park H, Waisman J, Yang ES, Spanggaard I, Reid S, Burkard ME, Vinayak S, Prat A, Arnedos M, Bidard FC, Loi S, Crown J, Bhave M, Piha-Paul SA, Suga JM, Chia S, Saura C, Garcia-Saenz JA, Gambardella V, de Miguel MJ, Gal-Yam EN, Rapael A, Stemmer SM, Ma C, Hanker AB, Ye D, Goldman JW, Bose R, Peterson L, Bell JSK, Frazier A, DiPrimeo D, Wong A, Arteaga CL, Solit DB. Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial. Ann Oncol. 2023 Oct;34(10):885-898. doi: 10.1016/j.annonc.2023.08.003. Epub 2023 Aug 18.
- Ueno NT, Cottone F, Dunton K, Jacot W, Yamashita T, Sohn J, Tokunaga E, Prat A, Tsurutani J, Park YH, Rugo HS, Xu B, Cardoso F, Mitri Z, Mahtani R, Aguilar CO, Xiao F, Harbeck N, Cameron DA, Modi S. Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician's choice of chemotherapy in patients with HER2-low mBC. Oncologist. 2025 May 8;30(5):oyaf048. doi: 10.1093/oncolo/oyaf048.
- Yamashita T, Sohn JH, Tokunaga E, Niikura N, Park YH, Lee KS, Chae YS, Xu B, Wang X, Im SA, Li W, Lu YS, Aguilar CO, Nishijima S, Nishiyama Y, Sugihara M, Modi S, Tsurutani J. Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study. Breast Cancer. 2024 Sep;31(5):858-868. doi: 10.1007/s12282-024-01600-7. Epub 2024 Jun 17.
- Ma R, Shi Y, Yan R, Yin S, Bu H, Huang J. Efficacy and safety of trastuzumab deruxtecan in treating human epidermal growth factor receptor 2-low/positive advanced breast cancer:A meta-analysis of randomized controlled trials. Crit Rev Oncol Hematol. 2024 Apr;196:104305. doi: 10.1016/j.critrevonc.2024.104305. Epub 2024 Mar 3.
- Rugo HS, Crossno CL, Gesthalter YB, Kelley K, Moore HB, Rimawi MF, Westbrook KE, Buys SS. Real-World Perspectives and Practices for Pneumonitis/Interstitial Lung Disease Associated With Trastuzumab Deruxtecan Use in Human Epidermal Growth Factor Receptor 2-Expressing Metastatic Breast Cancer. JCO Oncol Pract. 2023 Aug;19(8):539-546. doi: 10.1200/OP.22.00480. Epub 2023 May 19.
- Narayan P, Dilawari A, Osgood C, Feng Z, Bloomquist E, Pierce WF, Jafri S, Kalavar S, Kondratovich M, Jha P, Ghosh S, Tang S, Pazdur R, Beaver JA, Amiri-Kordestani L. US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer. J Clin Oncol. 2023 Apr 10;41(11):2108-2116. doi: 10.1200/JCO.22.02447. Epub 2023 Feb 13.
- Iyengar AR, Downs EP, Mehta S, Rangarajan N, Woo MS, Sredni ST, Donato RD, Simsek S, Wilson DM, Krieser K, Patzke EB, Kyek N, Anderson C, Wagner T, Hipp J, Nassar A, Barman H. HER2-Ultralow: Prevalence, Characteristics, and Treatment Choices Among Advanced Breast Cancer Patients With Tumors Initially Scored as IHC 0. Breast J. 2026;2026(1):e7212120. doi: 10.1155/tbj/7212120.
- Modi S, Jacot W, Iwata H, Park YH, Vidal Losada M, Li W, Tsurutani J, Ueno NT, Zaman K, Prat A, Papazisis K, Rugo HS, Yamashita T, Harbeck N, Im SA, De Laurentiis M, Pierga JY, Wang X, Gombos A, Tokunaga E, Orbegoso Aguilar C, Yung L, Xiao F, Cheng Y, Cameron D. Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial. Nat Med. 2025 Dec;31(12):4205-4213. doi: 10.1038/s41591-025-03981-4. Epub 2025 Oct 8.
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
- Patologické procesy
- Novotvary podle místa
- Novotvary
- Neoplastické procesy
- Kožní choroby
- Nemoci prsu
- Patologické stavy, příznaky a symptomy
- Onemocnění kůže a pojivové tkáně
- Novotvary prsu
- Metastáza novotvaru
- Organické chemikálie
- Heterocyklické sloučeniny, 1 kruh
- Heterocyklické sloučeniny
- Nukleové kyseliny, nukleotidy a nukleosidy
- Uhlovodíky
- Cykloparafiny
- Uhlovodíky, alicyklické
- Uhlovodíky, cyklické
- Terpeny
- Taxoidy
- Cyclodecanes
- Diterpeny
- Deoxycytidin
- Cytidin
- Pyrimidinové nukleosidy
- Pyrimidiny
- Nukleosidy
- Uracil
- Pyrimidinony
- Deoxyribonukleosidy
- Fluorouracil
- Kapecitabin
- Gemcitabin
- Paklitaxel
- 130 nm albumin vázaný na paclitaxel
- Trastuzumab deruxtecan
- Eribulin
Další identifikační čísla studie
- DS8201-A-U303
- 2018 (Grant/smlouva NIH USA)
- 2018-003069-33 (Číslo EudraCT)
- 184223 (Identifikátor registru: JAPIC CTI)
- DESTINY-B04 (Jiný identifikátor: Daiichi Sankyo and AstraZeneca)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
Časový rámec sdílení IPD
Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
Kritéria přístupu pro sdílení IPD
Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
Typ podpůrných informací pro sdílení IPD
- PROTOKOL STUDY
- MÍZA
- ICF
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .